Findings

What do systematic reviews say?

386 questions · 393 findings · 29 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 37 · 9.4%GRADE not reported 40 · 10.2%Very low 30 · 7.6%Low 90 · 22.9%Moderate 149 · 37.9%High 47 · 12%

Intervention not reported

HD‐ICS/LABA (Direct evidence; 7 RCTs; 5949 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 5949 participants
High

Intervention not reported

MD‐TRIPLE (Direct evidence; 3 RCTs; 3188 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3188 participants
Moderate

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCTs; 2039 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2039 participants
High

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 12 RCTs Total Participants: 12915 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 12915 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 7 RCTs; 5969 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 5969 participants
High

Intervention not reported

MD‐TRIPLE (Direct evidence; 3 RCTs; 3205 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3205 participants
Moderate

Intervention not reported

Moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2037(2 RCTs)

The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (high certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.78 [0.66, 0.92]
2 studies · 2037 participants
High

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCTs; 2051 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2051 participants
Moderate

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Moderate to severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2651(2 RCTs)

The intervention showed no clear difference in moderate to severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.05 [0.78, 1.41]
2 studies · 2651 participants
Low

Intervention not reported

Moderate to severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 4989(4 RCTs)

The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of… (high certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.83 [0.75, 0.92]
4 studies · 4989 participants
High

Intervention not reported

Moderate to severe exacerbations ‐ HD TRIPLE vs MD TRIPLE№ of participants: 3470(3 RCTs)

The intervention showed no clear difference in moderate to severe exacerbations ‐ HD TRIPLE vs MD TRIPLE№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.85 [0.72, 1.01]
3 studies · 3470 participants
Moderate

Intervention not reported

HD‐ICS/LABA (Direct evidence; 7 RCTs; 7023 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 7023 participants
Moderate

Intervention not reported

Moderate to severe exacerbations ‐ TRIPLE vs DUAL№ of participants: 8173(5 RCTs)

The intervention leads to lower moderate to severe exacerbations ‐ TRIPLE vs DUAL№ of participants:… (high certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.85 [0.78, 0.92]
5 studies · 8173 participants
High

Intervention not reported

Total studies: 10 RCTs Total Participants: 12407 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 12407 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 6 RCTs; 5452 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 5452 participants
High

Intervention not reported

MD‐TRIPLE (Direct evidence; 3 RCTs; 3184 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3184 participants
Moderate

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCTs; 2037 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2037 participants
High

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found